9 research outputs found
How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?
Prostate cancer (PC) is a hormone-sensitive tumor. Androgen deprivation therapy (ADT) is the cornerstone of systemic therapy for patients with intermediate or high-risk localized, recurrent, and metastatic prostate cancer. Although generally well tolerated, ADT can lead to short- and long-term adverse events that can worsen the quality of life of patients with PC. In the last decade, the introduction of novel generation androgen receptor pathway inhibitors (ARPI) has resulted in an improvement in the prognosis of patients with metastatic PC when used in combination with ADT. The use of ARPI in increasingly early stages of the disease determines a longer exposure of patients to these treatments. Although ARPIs are normally well-tolerated drugs, they generally cause an increase in toxicity compared to ADT alone, being able to worsen some adverse events already induced by ADT or leading to the development of specific side effects. Although there are no specific treatments for all the adverse events induced by hormonal therapies, it is essential to know the possible toxicities induced by the different treatments and to start procedures to prevent and/or recognize and consequently treat them early in order to not compromise the quality of life of the patients with PC. The aim of this review is to describe the adverse events induced by hormonal therapies. We will first describe the side effects induced by both ADT and ARPI and then the specific adverse events of the different ARPIs. Furthermore, we will try to highlight the possible therapeutic options to prevent or mitigate the toxicity induced by hormone therapies in order to improve the quality of life of the patients with PC
Supplementary Figure 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial
Supplementary Figure 1. ID patients 10# IGV screen of BAP1 c.38-1G>T variant.</p
Supplementary Figure 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial
Supplementary Figure 2. Keplen Maier curves for survival outcomes in the overall analyzed population.</p
Supplementary Figure 3 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial
Supplementary Figure 3. ID patients 3# IGV screen of BRCA2 p.A406Lfs*9 variant.</p
Supplementary Table 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial
Supplementary Table 1. Representativeness of Study Participants.</p
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
Urothelial cancer is a lethal malignancy characterized by a wide diffusion in Western countries due to a larger exposure to known risk factors, such as aromatic amines, tobacco smoke and benzene [...
Supplementary Table 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial
Supplementary Table 2. Clinical Responses to Niraparib plus Dostarlimab in the analyzed population.</p